Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI and Health-related Quality of Life in Autoimmune Patients Switched from MMF to Myfortic
2005-002233-12Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mycophenolate sodium in autoimmune disease, sponsored by Novartis. Primary endpoints: Primary GI and HRQL Questionnaire Response Change and Proportion of Patients with GI Symptoms Under MMF. Started Oct 2006; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on 2005-002233-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002233-12.